Brief: Infant Bacterial Announces Phase III IBP-9414 Study Results

Infant Bacterial Therapeutics AB

03/03/2026 06:08

March 3 (Reuters) - Infant Bacterial Therapeutics AB IBTb.ST:

ANNOUNCES PHASE III STUDY RESULTS PUBLISHED IN PEDIATRIC RESEARCH

PHASE III STUDY SHOWS 27% MORTALITY REDUCTION WITH IBP-9414

TREATMENT DESIGNATED AS 'BREAKTHROUGH THERAPY' AND 'RARE PAEDIATRIC DISEASE'

STUDY CONCLUDES IBP-9414 REDUCES MORTALITY AND NECROTIZING ENTEROCOLITIS

Source text: ID:nMFN14WYNf

Further company coverage: [IBTb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))